BOSTON, Dec. 7, 2021 /PRNewswire/ — Delix Therapeutics (the “Company”), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, today announced a partnership with The National Institute on Drug Abuse (NIDA), a federal scientific research institute under the U.S. Department of Health and Human Services’ National Institutes of Health (NIH)…


Previous articleEditor’s Choice Award 2021-Best Study on Psychedelics and Nature
Next articleMindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System